Medicine
Xultophy 100/3.6 100 IU/3.6 mg per mL injection
Xultophy 100/3.6 100 IU/3.6 mg per mL injection is a prescription medicine containing Insulin degludec and Liraglutide for subcutaneous use, marketed by Novo Nordisk, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Do not store in the freezer or directly adjacent to the refrigerator cooling…
Key facts
- Active ingredient (INN)
- Insulin degludec and Liraglutide
- Brand
- Xultophy 100/3.6
- Strength
- 100 IU/3.6 mg per mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 5 syringes
- Marketing authorisation holder
- Novo Nordisk
- Manufacturer
- Novo Nordisk
- Origin register
- US FDA, United States
- Storage
- Do not store in the freezer or directly adjacent to the refrigerator cooling element. Do not freeze. Prior to first use, XULTOPHY 100/3.6 should be stored between 36°F to 46°F (2°C and 8°C) until the expiration date printed on the label.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A10AE56 Insulin degludec and Liraglutide
- HS code (indicative)
- 3004.31Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 21 November 2016
- Identifiers
- RxCUI 1860167, 1860172DailyMed set ID 21335fe4-d395-4501-ac2a-2f20d7520da9NDC 0169-2911Application BLA208583
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 5 syringe, plastic in 1 carton / 3 mL in 1 syringe, plastic | 0169-2911-15 | Novo Nordisk | 21 November 2016 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Insulin degludec and Liraglutide is a fixed-dose combination of a GLP-1 receptor agonist and an insulin analog. It is available as injection for subcutaneous use. MedsAcross supplies Insulin degludec and Liraglutide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Insulin degludec and LiraglutideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Xultophy 100/3.6 prescribing information (Novo Nordisk) · U.S. National Library of Medicine, DailyMed
- Xultophy: European public assessment report (EPAR) · European Medicines Agency
Need Xultophy 100/3.6 100 IU/3.6 mg per mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.